The current gene transfer technology for single chain (scFv)-based chimeric immune receptor (CIR) has relied on retrovirus and lentivirus vectors which require a long time to obtain sufficient number of transduced cells and stably incorporate into genome. To ameliorate these limitations, we applied RNA electroporation to human peripheral blood lymphocytes (PBLs) activated with anti-CD3 antibody and interleukin-2 (IL-2) for 3 days and assessed that PBL transiently expressing anti-Her-2/neu CIR (CIR-PBL) containing signaling portion of CD28 and CD3z could elicit strong cytotoxicity in vitro and antitumor responses in vivo. The CIR-PBL expressed high level of CIR in CD4 þ , CD8 þ and CD56 þ cells. Her-2/neu-specific stimulation induced secretion of type-I cytokines including interferon-g (IFN-g), IL-8 and granulocyte-macrophage colony-stimulating factor, and IFN-g secretion was mainly mediated by CD8 þ T cells. CIR-PBL specifically killed SKOV3 cell line expressing Her-2/neu. Adoptive transfer of CIR-PBL in SKOV3 xenograft model led to significant inhibition of tumor growth compared with transfer of mock-transduced PBL and showed higher inhibition than those with Herceptin, humanized monoclonal antibody specific for Her-2/neu. These results provided evidence that electroporation of CIR RNA to human PBLs could be used for rapid generation and high number of therapeutic antigen-specific T cells for adoptive immunotherapy.
Introduction
Adoptive transfer of cytotoxic T lymphocytes (CTL) has shown great promises in both viral infections and cancers, and has become one of the most effective treatments for immediate regression. Epstein-Barr virus (EBV)-associated lymphoma can be targeted using long-termcultured EBV-specific CTL and adoptive transferred cells persisted up to 3 years in patients. 1 Moreover, tumorinfiltrating lymphocytes from patients with melanoma could be successfully cultured in vitro and showed effector functions against melanoma antigens when reinfused into patients. 2, 3 However, reactive T cells against tumor antigens cannot be generated in every case due to individual variations and priming capacity of antigenpresenting cells. Even if T cells are generated with high avidity for antigens, the success of adoptive T-cell immunotherapy cannot be guaranteed because of uncertainty of its persistency and reactivity in vivo. 4 The genetic modification of T-cell function allowed naı¨ve T cells transformed into tumor-reactive effector cells harboring high affinity T-cell receptors (TCRs) as well as chemokine and cytokine receptors that enhance their survival and homing properties. 5 Rosenberg and co-workers 6 reported from the first clinical trial that 2 out of 16 patients, who received autonomous lymphocytes expressing MART-1 TCR, underwent regression of liver and lung helium metastases and showed complete regression over 2 years later. In addition to TCR gene transfer, several studies have performed clinical trials using T lymphocytes genetically modified to express chimeric immune receptor (CIR) containing scFv. Since the first generation of CIR using only extracellular antigen-binding domain and CD3z signaling portion, studies have focused on the use of costimulatory domains including intracellular-signaling chains of CD28 and 4-1BB so that maximal T-cell activation can be efficiently optimized and the antitumor responses can be maintained upon antigen-receptor ligation. [7] [8] [9] Poor expression of major histocompatibility complex (MHC) and costimulatory molecules by tumors may be one of limitation of adoptive cell transfer therapy using TCR. 10 The approach with scFv-CIR can avoid MHC limitations imposed by the use of TCR, thus stable transfectants expressing CIR has shown its therapeutic potentials against several surface tumor antigens. 11, 12 Long-term persistency and expansion of gene-modified lymphocytes can be mediated by retroviral or lentiviral transduction. However, regulatory concerns on their potential for insertional mutagenesis and genotoxicity increase the need of alternative method. [13] [14] [15] [16] The frequently targeted antigens including Her-2/neu, carcino embryonic antigen, TAG-72, CD20, CD30 and prostate stem cell antigen are also expressed in normal cells or tissues, thus safety concerns of long-term genetic modification remain to be resolved. The recent study showed that gene transfer to T cells by RNA electroporation reaches up to 90% efficiency without any critical toxicity and onset of transgene expression is very rapid. 17 The use of RNA has been previously applied to dendritic cells for antigen loading and demonstrated its high efficiency for eliciting CD4 þ and CD8 þ immune responses. 18 Her-2/neu is a growth factor receptor, abnormally overexpressed in breast and ovarian cancers. Despite of early treatment with surgical and chemotherapy, women with disease having Her-2/neu amplification shows poor disease-free survival due to its aggressive form. [19] [20] [21] [22] Many methods have been used to therapeutically target Her-2-overexpressing cancers, including the use of anti-Her-2/neu antibodies. [23] [24] [25] [26] Trastuzumab also known as Herceptin for humanized form, was found to inhibit the proliferation of human cancer cells that overexpress Her-2/neu, both in vitro and in vivo. 27, 28 However, the clinical benefit is limited because its resistance to Herceptin therapy among Her-2/neu-overexpressing cancer cells arises in less than 12 months. [28] [29] [30] This indicates that inhibition of proliferation by physically interfering dimerization of the receptors and blocking downstream Her-2/neu signaling are not sufficient for complete eradication.
As RNA electroporation is safe and technically convenient in preparation, we investigated the applicability of RNA encoding CIR against Her-2/neu antigens in terms of transfection efficiency, antitumor effects and comparison with Herceptin in vivo. Our results provide evidence that transient expression of CIR in human peripheral blood lymphocytes (PBLs) could be a useful strategy of adoptive T-cell therapy for the treatment of cancer.
Materials and methods

Cells and antibodies
The human ovarian cancer cell line SKOV3, which expresses the Her-2/neu antigen, and Her-2/neu-negative breast cancer cell line MCF7 was maintained in Dulbecco's modified Eagle's medium with the following additives: 10% (v/v) fetal bovine serum (FBS), 2 mM glutamine, penicillin (100 U ml
À1
) and streptomycin (100 mg ml À1 ) (Invitrogen GIBCO, Grand Island, NY). The following monoclonal antibodies (mAbs) were used in this study: 9E10 (mouse anti-cMyc fluorescein isothiocyanate (FITC) conjugated) (Sigma, Saint Louis, MO); mouse anti-human CD4, CD8, CD56 PE-conjugated (BD, San Jose, CA), anti-CD3 mAb (OKT3; Ortho Biotech Inc., Raritan, NJ), anti-Her-2/neu mAb (Herceptin; Genentech, Thousand Oaks, CA) and anti-IFN-g FITC-conjugated mAb (eBioscience, San Diego, CA, USA).
In vitro transcription of mRNA The CIR containing anti-Her-2/neu scFv joined to intracellular portion of CD28 and CD3z was kindly provided by Dr Philip K Darcy (Peter MacCallum Cancer Centre, Australia). The CIR construction was subcloned to pCDNA3.1 vector (Invitrogen GIBCO) containing T7 promoter proximal to start codon of the backbone. The mMESSAGE mMACHINE High Yield Capped RNA Transcription Kit (Ambion Inc., Austin, TX, USA) was used to synthesize in vitro transcription (IVT) RNA. After IVT, the mRNA was purified using Phenol:Chloroform (Sigma) and purified RNA was eluted in RNase-free water at 4-5 mg ml
.
Transduction of primary human PBLs
Transduction of human PBL was performed as described previously. 15 Briefly, peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated by FicollPaque density centrifugation (GE Healthcare BioSciences, Uppsala, Sweden). PBLs were isolated from human PBMCs by depleting CD14 þ cells using microbeads (Miltenyi, Auburn, CA, USA). CD14-PBLs were activated with OKT3 (500 ng ml
À1
) and recombinant human interleukin-2 (IL-2, 600 IU ml
; eBioscience) for 3 days. Stimulated PBLs were harvested and resuspended at 1 Â 10 6 cells per 100 ml in OPTI-MEM (Invitrogen GIBCO) containing various dose of mRNA. Cells were electroporated in 2-mm cuvettes at 400 V for 500 ms, using a square waveform generator (ECM 830 Electro Square Porator; BTX, a division of Genetronics, San Diego, CA). The electroporated PBLs were immediately transferred to medium containing 10% FBS and IL-2 (600 IU ml À1 ) and cultured in 24-well tissue culture plates (2 ml per well). The next day, cells were harvested and used for flow cytometry analysis or functional assay. PBLs were grown in RPMI 1640 medium supplemented with 10% (v/v) FBS, 2 mM glutamine, penicillin (100 U ml
) and streptomycin (10 mg ml À1 ) (Invitrogen GIBCO). The experimental protocol was approved by the local Ethics Committee of the Catholic University of Korea.
Evaluation of apoptosis
Apoptosis was detected by dual staining with FITCconjugated annexin V (BD PharMingen, San Diego, CA, USA) and propidium iodide (PI) (Sigma-Aldrich, Gillingham, UK). Transduced PBLs were divided into six wells and cultured for 6 days. At each day, cells from one of the six wells were harvested and stained for apoptosis.
Intracellular staining assay
A total of 1 Â 10 6 cells of RNA-modified PBLs from each donor were incubated with SKOV3 or MCF7 cells in the presence of 10 mg ml À1 of Brefeldin A (Golgiplug; PharMingen, San Diego, CA) and incubated for 18 h in 37 1C. Cells were then harvested, washed and permeabilized with CytoFix/Cytoperm solution (PharMingen). Cells were stained with PE-conjugated CD4, CD8 or CD56 antibodies for 30 min at 4 1C. After washing two times, cells were permeabilized and stained with interferon (IFN)-g Ab for additional 20 min, and finally analyzed with a FACSCalibur by collecting 10 000 total events.
Cytokine production assays
Cytokine secretion by transduced PBLs upon encountering target antigen was detected by 8-plex cytokine beads array (Bio-Rad, Hercules, CA) or enzyme-linked immunosorbent assay (ELISA) (eBioscience). Briefly, CIR or mock-transduced PBLs (1 Â 10 6 cells per ml) were incubated with Her-2/neu-positive cells, SKOV3, or control MCF7 cells (Her-2/neu negative) in 96-well U-bottom plates for 24 h at 37 1C. Supernatants were harvested and IFN-g, tumor-necrosis factor-a (TNF-a), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-2, IL-4, IL-6, IL-8 and IL-10 secretion by CIR-PBLs were determined.
ELISPOT assays
A commercially available ELISPOT kit was used (AID, Jessup, MD). PBLs stimulated for 3 days with OKT3 and IL-2 were transduced with RNA encoding anti-Her-2/neu. Cells were harvested, counted and incubated in the well with a cell density of 5 Â 10 2 cells per well. SKOV3 or MCF7 cells (50 cells per well) were used as stimulators and coincubated with PBLs. The mixture of cells was cultured into an IFN-g-coated ELISPOT plate for 20 h. To visualize spots, streptavidin-horseradish peroxidase and substrate were used. Spots were counted after computerized visualization using a reader (AID).
Cytotoxicity assay
The cytolytic capacity of transduced PBLs was assessed in a standard 4-h 51Cr release assay. Briefly, PBLs were used after stimulation in the presence of OKT3 and IL-2 for 3 days. On day 3, PBLs were harvested, washed, resuspended in OPTIMEM and electroporated with IVT mRNA. Transduced PBLs were twofolds serially diluted from 16:1 and was incubated for 4 h at 37 1C with Xenograft model A total of 10 female 4-week-old nude mice (Balb/c nu/nu; Charles River, Sulzfeld, Germany) per group were used. They were housed in filter top cages and provided with water and food. All mice were ear tagged, and their individual tumor volume was monitored during the experiment. After 1 week of acclimatization, they were inoculated subcutaneously (26-guage needle) with 1 Â 10 7 SKOV3 cells in a 0.4-ml single-cell suspension. After tumors become palpable, the antitumor efficacy of 5 Â 10 6 CIR-PBLs was assessed and compared to that of mock-PBLs or Herceptin (20 mg kg À1 ) (Roche, Nutley, NJ, USA). PBLs were intratumorally (i.t.) injected and intraperitoneally (i.p.) for Herceptin. The treatments were performed thrice with a week interval and mice were monitored daily for tumor growth. Following treatment, the tumor volume (mm 3 ) was estimated in accordance with the formula (tumor width 2 Â tumor length/2). All animals were handled according to the local and national regulations, and the local ethics committee approved the protocol.
Statistical analysis
Statistical analysis was performed using the two-tailed Mann-Whitney nonparametric test for tumor volume measurement and the two-tailed Student's t-test for cytokine assay.
Results
Electroporation of CIR RNA to activated PBL After 3 days of stimulation with OKT3 and IL-2, human PBLs were electroporated with RNA encoding CIR against Her-2/neu antigen. To find out the optimized concentration of RNA, IVT RNA was serially diluted starting from 20 mg and CIR expression was analyzed by flow cytometry. CIR expressed on the surface of PBLs at as low as 0.625 mg of RNA and the intensity of expression gradually increased as more of RNA was used (Figure 1a ). In the following experiments, 10 mg of IVT RNA was used to generate CIR-PBL. We also examined expression of the CIR in subsets of PBLs after electroporation and found CIR expression in more than 95% of CD4 þ , CD8 þ and CD56 þ cells (range, 90-99% in repeated experiments). Activated PBLs without electroporation displayed a negligible expression of CIR (range 0-2%, data not shown) (Figure 1b) .
Her-2/neu-specific cytokine secretion and tumor-cell lysis The immunological characteristics of CIR-PBL were compared by different in vitro assays. We first showed the cytokine profile of CIR-PBL on antigen stimulation with positive target cell, SKOV3, and negative target cell, MCF7. As shown in Figure 2a , CIR-PBL produced significantly higher levels of IL-8, GM-CSF and IFN-g upon antigen stimulation compared with MCF7 or media only. CIR-PBL also produced high level of IL-4 and TNF-a (Po0.05), but did not produce detectable level of the cytokines in stimulation with MCF7 or media only. Consistent with previous studies, 9 CIR-PBL produced basal level of IL-2 cytokines following stimulation with antigen-positive tumor targets (Figure 2a) .
On the basis of the data, we next examined which subset of the PBLs is responsible for secretion of IFN-g by intracellular staining (ICS) assay. Although high level of CIR expression was observed in CD4 þ , CD8 þ and CD56 þ population (Figure 1b) , the percentage of IFN-gsecreting cells upon stimulation with MCF7 or SKOV3 cell lines were 1.5±0.2 vs 3.0±0.6% for CD4 þ , 2.9±0.7 vs 16.7 ± 3.5% for CD8 þ and 0.2 ± 0.1 vs 0.7 ± 0.2% for CD56 þ , respectively. To quantitate the frequency of IFN-g-secreting CIR-PBL, we have performed the ELISPOT assay with various numbers of CIR-PBL to set experimental conditions. Only a range of 500 cells or fewer could yield detectable number of spots in a single well due to the high expression of CIR by RNA electroporation. As shown in Figure 3a , a median of 32 spots were formed when incubated with SKOV3 for 20 h and the spots are specific for Her-2/neu because less than 2 spots were formed in 3 different donors upon stimulation with MCF7 cells. These results indicate that 5-7% of CIR-PBL may have protective immune reactivity specific for Her-2/neu antigen.
Lastly, we compared the ability of CIR-PBL to mediate specific lysis of SKOV3 target cells in a 4-h 51 Cr-release assay. CIR-PBL specifically lysed Her-2/neu-positive SKOV3 cells (Figure 3b) but not negative tumor cell, MCF7. Lysis of SKOV3 was dependent on expression of CIR as no lysis by mock-transduced PBLs was observed (data not shown). Any significant difference of cytolytic activity was not observed among three donors suggesting that individual variation could be reduced due to high density of CIR expression. Furthermore, CIR-PBL showed very high cytotoxicity of more than 60% at low E:T ratio as 8:1. Taken together, these data demonstrated that PBLs could be effectively transduced with the RNA encoding CIR and mediate antigen-specific release of type-I cytokines and cytotoxic activity. Moreover, the data suggest that the major subset that is responsible for IFN-g secretion is CD8 þ T cells although CD4 þ and CD56 þ T cells also expressed anti-Her-2/neu CIR (Figure 2b ).
Duration of RNA expression and viability of RNAmodified PBLs in vitro
As we observed strong cytotoxicity of CIR-PBL, we further defined the kinetics of viability, CIR expression and reactivity to Her-2/neu in vitro to preview the capacity of CIR-PBL in vivo. When CIR-PBL is incubated in media containing no exogenous IL-2 after electroporation, CIR-PBL did not Figure 1 Chimeric immune receptor (CIR) expression by RNA electroporation in activated human peripheral blood lymphocytes (PBLs). After 3 days of in vitro stimulation with OKT3 and interleukin-2 (IL-2), RNA encoding CIR was electroporated as indicated (two times dilution from 20 mg) into 1 Â 10 6 stimulated PBLs in 100 ml volume. CIR expression was detected by flow cytometry after 16 h (a). RNA of anti-Her-2/neu CIR was electroporated into 1 Â 10 6 stimulated PBLs in 100 ml volume. Expression of anti-Her-2/neu CIR in subpopulations of PBLs was stained with fluorescein isothiocyanate (FITC)-conjugated anti-cMyc mAb (b). To determine the RNA transduction of PBL subsets, samples were also stained either with PE-conjugated anti-human CD4, anti-human CD8 or anti-human CD56 mAb and analyzed by two-color flow cytometry.
proliferate any more, rather the cell number was rapidly decreased to about 40% after day 1 and then gradually reached plateau until day 6 (Figure 4a ). This is further verified by apoptosis assay using flow cytometry (Figure 4a ). The percentage of annexin V-and PI-stained cells increased from about 13% on day 0 to more than 30% after day 4.
Next, we tested kinetics of CIR expression as shown in Figure 4b . Electroporation with 10 mg of RNA resulted in about 68 mean fluorescence intensity (MFI) and 99.66% of cells were positive for CIR expression on day 1. On day 2, the expression intensity is decreased to about one third, but CIR-positive cells are still more than 99%. On day 3, the MFI decreased again to one-third of that observed a day before, but about 80% of cells still expressed MFI. Since day 3, the MFI of CIR expression remained about 8-10, but about 60% of cells continued to express CIR on surface until day 5.
Lastly, duration of antigen-specific response was tested against Her-2/neu-positive SKOV3 cells. Figure 4c shows the IFN-g secretion by CIR-PBL, in comparison to mocktransduced PBLs as a control. A high level of IFN-g production (1185 pg ml
À1
) was induced on day 1 upon stimulation with SKOV3 cells. As observed in CIR expression by flow cytometry, cytokine-producing potency on day 2 also decreased rapidly about one-third (395 pg ml À1 ) of that observed on day 1. Taken together, there is no significant change in cell number in IL-2 deprivation condition, but the percentage of cells entering into apoptotic phase are increasing and the intensity of CIR expression and functionality of CIR-PBL are decreasing.
Antitumor responses by CIR-PBLs and Herceptin in vivo
To examine whether transient expression of CIR could generate strong antitumor response in vivo, we compared the potency of CIR-PBL to mock-transduced PBLs and Herceptin in terms of tumor volume in xenograft model. A total of 1 Â 10 7 cells of SKOV3 were subcutaneously injected in athymic nude mice and we let the tumor cells grow until the volume reaches to 100-200 mm 3 after 7 weeks. Treatment was weekly performed for 3 weeks and tumor growth was monitored. Even in a late-phase treatment, we clearly demonstrated CIR-PBL elicited strong antitumor responses and showed significant slow tumor progression than the control mice treated with phosphate-buffered saline (PBS) only (Po0.001) ( Figure 5 ). The control mice had tumors with a mean volume of 2486 mm 3 at day 28 after treatment, which represented 2.5-fold increase in tumor volume than mice treated with CIR-PBL. Although tumors treated with mock-PBL are smaller than those in the PBS control group, CIR-PBL showed higher tumor inhibition than mock-PBL (1.5-fold, P ¼ 0.0021). Therefore, the enhanced antitumor response may be mainly dependent on anti-Her-2/neu CIR. Mice treated with Herceptin had tumors with a mean volume of 1395 mm 3 compared with those with CIR-PBL, 999 mm 3 (P ¼ 0.0433) ( Figure 5 ). Herceptin-mediated inhibition was intermediate although the inhibition rate in mice treated with Herceptin was clearly high compared to those with PBS or mock-PBL. Our results suggest that adoptive cellular therapy by CIR-PBL could elicit strong antitumor effects in vivo despite of the observation that CIR-PBL cannot persist long term in vitro.
Discussion
Use of genetically modified lymphocytes harboring receptors specific for antigens has shown great promises in both viral infections and tumors. ScFv-based CIR approaches is advantageous for adoptive immunotherapy that T cells can recognize target cells based on the surface expression of antigen and are able to kill in an MHCunrestricted fashion rather than processed antigens. [7] [8] [9] Most of the reports on scFv-engineered T cells are dependent on retro-or lentivirus for genetic modification. [7] [8] [9] Despite of its efficiency in generating stable transfectants through drug selection, the time and labor required for establishing transduced clones limits clinical applicability. By the time therapeutic numbers of transfectants are obtained, cells will be exhausted due to the Adoptive immunotherapy using CIR-RNA SH Yoon et al long-term selection, which results in shortening of telomere, expressing low levels of activation markers, poor proliferation and short-term persistency in vivo.
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Therefore, we show in this study that RNA electroporation is an efficient nonviral gene transfer technology that facilitates high transduction efficiency and rapid generation of large number of scFv-engineered T cells for cancer therapy ( Figure 1 ). As shown in other studies, activation with OKT3 and IL-2 before electroporation was prerequisite for our study because electroporation of unstimulated human PBLs with RNA resulted in undetectable level of expression and viability was critically low (data not shown). 17 To optimally transfer genes into naı¨ve T cells, there should be more assessment of electroporation condition in future study. Nevertheless, RNA electroporation to activated PBLs allowed high efficiency of gene expression in CD4 þ , CD8 þ and CD56 þ T cells (495%), which resulted in 5-7% of PBLs to secrete IFN-g upon antigen ligation as analyzed by ELISPOT (Figures 1 and 3) .
In this study, we used PBLs to assess its efficacy in Her-2/neu targeting both in vitro and in vivo instead of purified CD4 þ or CD8 þ T cells. The primary reason is that we wanted to avoid as many manipulation steps as possible before adoptive transfer. Second, it was unnecessary to isolate CD8 þ T cells for adoptive transfer because we found out that CD4 þ T cells do not secrete significant amount of Th-2 type cytokines (Figure 2a) . Furthermore, our result from ICS assay showed that the percentage of IFN-g-secreting T cells was 17% for CD8 þ and 3% for CD4 þ T cells, indicating that the response is mainly mediated by CD8 þ T cells even in the mixture of subsets (Figure 2b) . In contrast to our use of PBLs, most studies have performed experimental studies with CD8 þ T cells alone. However, adoptive transfer of CD8 þ T cells alone is largely ineffective against more established disease. 8, 9 It was demonstrated both in viral infection and tumor models that CD4 þ T cells support CD8 þ T cells for full activation by providing costimulatory signals and necessary cytokines. [32] [33] [34] [35] Nonetheless, a concern on the use of PBLs may arise because a portion of CD4 þ T cells exerts Th2 response. However, a number of studies demonstrated that the antigen-specific support from both Th1 and Th2 cells is also critical when CD8 þ T cells are rechallenged for memory responses. 31, 36 Moreover, the construct of CIR contains signaling portion of CD28 and CD3z which provides costimulatory signals and promotes secretion of more of type-I cytokines including IFN-g and TNF-a. 37 In the same aspect, the lack of signaling domain from DAP12 may explain why natural killer (NK) cells expressing CIR were not as effective as CD8 þ T cells (Figure 2b ).
In our model with athymic nude mouse, we demonstrated that both CIR-PBL and Herceptin slowed down tumor growth ( Figure 5 ). However, Herceptin showed intermediate effect compared to CIR-PBL, which may be due to late-phase treatment. Although CIR-PBL showed higher rate of tumor inhibition than Herceptin in our study, more aggressive treatment with Herceptin including frequent infusion and the use of higher dose can result in better clinical outcome than infusion of CIR-PBL, as used by other groups. [23] [24] [25] [26] Several reports have contributed to elucidate mechanism of Herceptin including interference receptor dimerization, blockade of phosphorylation of ErbB2 and ErbB3, inhibition of mitogen-activated protein kinase activity, and suppression of phosphatidylinositol 3 0 -kinase, and Akt. 38, 39 In addition, it was proposed that Herceptin generates antibody-dependent cell-mediated cytotoxicity effect involving host NK cells. 40 On the basis of these findings, the treatment of Herceptin has been a standard therapy for Her-2/neu-overexpressing cancers and the efficacy is enhanced by combination with chemotherapy. Herein, we add one more immunotherapeutic strategy using CIR-PBL in treatment of Her-2/neu that may lead to improvements of clinical outcome.
For safety issue, the use of RNA into primary T cells circumvents the removal strategy. This is supported with our finding that the expression of targeted protein is transient and gradually decreasing as shown in Figure 4 . However, it is necessary to examine the kinetics of CIR expression and the survival of CIR-PBL further in vivo and adjust the experimental protocol to inject the therapeutic cells more frequent. This would definitely enhance disease outcome and result in complete eradication. In support of utility of RNA electroporation to primary T cells, a recent study demonstrated that employing IVT RNA encoding chemokine receptor, CXCR2, allows antigen-specific T cells to migrate preferentially into the peritoneal cavity and the central nervous system in response to CXCR2-specific ligands. 10 This technology can be further applied by multiple gene transfer. For instance, the survival of T cells can be enhanced by cotransfer of CIR and IL-2 in vivo, or CIR and 4-1BB ligand for full activation by delivering costimulatory signals in autocrine fashion. Moreover, most of the tumor cells express multiple tumor-associated antigens, thus T cells can be redirected with combination of scFv-CIRs to elicit antitumor responses against several tumor antigens. 41 Our results demonstrate for the first time in vivo that PBLs electroporated with RNA encoding anti-Her-2/neuspecific CIR elicit potent immune responses against Her-2/neu-overexpressing SKOV3 tumors. To be more feasible, it is necessary to examine further on optimal conditions including cell numbers to inject, injection interval and route in immune-competent model. Although we could not present the direct comparison of efficacy between stably and transiently expressing clones, the RNA modification of PBLs may be potentially useful for large-scale genetic modification of T lymphocytes required for clinical applications.
